Pharvaris N.V. (PHVS): Price and Financial Metrics
PHVS Price/Volume Stats
| Current price | $26.90 | 52-week high | $33.00 |
| Prev. close | $26.69 | 52-week low | $6.02 |
| Day low | $26.36 | Volume | 113,300 |
| Day high | $28.28 | Avg. volume | 137,900 |
| 50-day MA | $27.55 | Dividend yield | N/A |
| 200-day MA | $18.91 | Market Cap | 856.50M |
PHVS Stock Price Chart Interactive Chart >
Pharvaris N.V. (PHVS) Company Bio
Pharvaris B.V. operates as a clinical-stage company. The Company focuses on the discovery and development of novel oral B2-receptor antagonists for the treatment of patients. Pharvaris serves customers in the Netherlands and Switzerland.
Latest PHVS News From Around the Web
Below are the latest news stories about PHARVARIS NV that investors may wish to consider to help them evaluate PHVS as an investment opportunity.
Pharvaris N.V.'s (NASDAQ:PHVS) largest shareholders are private equity firms who were rewarded as market cap surged US$578m last weekKey Insights Significant control over Pharvaris by private equity firms implies that the general public has more power... |
Pharvaris Presents Deucrictibant Clinical Data and Analysis of Endpoints for Trials of On-demand Treatment of HAE at the GA²LEN UCARE Conference 2023ZUG, Switzerland, Dec. 08, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the presentation of one oral session and two posters at the Global Allergy and Asthma Excellence Network (GA²LEN) Urticaria Centers of Reference and Excellence (UCARE) Conference, being held from December 7-9, 2023, at the Rebouças Convention Center in São Paulo, B |
Pharvaris (PHVS) Stock Up 18% on HAE Drug Meeting Study GoalData from a mid-stage study shows that treatment with Pharvaris' (PHVS) investigational HAE drug reduced the monthly attack rate by 84.5%. |
Biotech Stock Roundup: EXEL Partners RCUS for Study, PHVS & EYPT Gain on Study DataUpdates from Exelixis (EXEL) and Pharvaris (PHVS) are in the spotlight this week. |
AMD Stock Alert: What to Expect From Advanced Micro Devices ‘Advancing AI’ EventAdvanced Micro Devices stock is climbing higher on Wednesday as AMD investors prepare for the company's Advancing AI event today. |
PHVS Price Returns
| 1-mo | -1.43% |
| 3-mo | 73.32% |
| 6-mo | 34.50% |
| 1-year | 209.55% |
| 3-year | -25.09% |
| 5-year | N/A |
| YTD | -4.10% |
| 2023 | 149.33% |
| 2022 | -21.82% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...